High density lipoproteins (HDL) possess beneficial activities that protect against atherosclerosis. The beneficial effects of HDL are related, in part, to its constituent proteins, such as apolipoprotein(apo) A-I and E, that facilitate the antiatherogenic reverse cholesterol transport (RCT) pathway. Stimulation of cellular cholesterol efflux by apoA-I and E constitutes the rate-limiting step in RCT that generates HDL and reverses the macrophage foam-cell phenotype. These events require the ATP-binding cassette transporter A1 (ABCA1). As a result, ABCA1 is clinically relevant and represents an attractive target for therapeutic interventions to combat atherosclerosis. The long-term objectives of these studies seek to define the molecular basis by which apolipoprotein family members interact with membrane transporters such as ABCA1, identifying fundamental principles and forces that govern and direct the RCT process. The information will be translated into therapeutics to combat diseases of aberrant cholesterol homeostasis. Based on comparative analyses of apoA-I and E C-terminal domains, a high-affinity functional-ligand for ABCA1 was created. The proposed studies will utilize a mouse model of human disease to test whether this novel consensus peptide increases plasma HDL concentrations, promotes RCT activity in vivo, and stimulates the regression of atherosclerotic lesions. The research is of broad biological- and clinical-relevance for understanding how HDL proteins remove excess cholesterol from the artery wall. A new class of therapeutics will be developed based on small peptides formulated from HDL proteins. The research is likely to have a high impact on public health, since the therapeutics will be amenable to the widespread treatment of atherosclerosis. ? ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21HL085791-01A1
Application #
7257930
Study Section
Special Emphasis Panel (ZRG1-CVS-Q (90))
Program Officer
Wassef, Momtaz K
Project Start
2007-04-01
Project End
2009-03-31
Budget Start
2007-04-01
Budget End
2008-03-31
Support Year
1
Fiscal Year
2007
Total Cost
$203,550
Indirect Cost
Name
Lawrence Berkeley National Laboratory
Department
Neurosciences
Type
Organized Research Units
DUNS #
078576738
City
Berkeley
State
CA
Country
United States
Zip Code
94720
Bielicki, John K (2016) ABCA1 agonist peptides for the treatment of disease. Curr Opin Lipidol 27:40-6
Zheng, Ying; Patel, Arti B; Narayanaswami, Vasanthy et al. (2013) Retention of ?-helical structure by HDL mimetic peptide ATI-5261 upon extensive dilution represents an important determinant for stimulating ABCA1 cholesterol efflux with high efficiency. Biochem Biophys Res Commun 441:71-6
Zheng, Ying; Patel, Arti B; Narayanaswami, Vasanthy et al. (2011) HDL mimetic peptide ATI-5261 forms an oligomeric assembly in solution that dissociates to monomers upon dilution. Biochemistry 50:4068-76
Bielicki, John K; Zhang, Haiyan; Cortez, Yuan et al. (2010) A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice. J Lipid Res 51:1496-503